Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Exclusion Criteria

• •To participate in this study, subjects must not meet any of the following criteria:
• •1. Significant suicide risk as defined by either suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening, or at Baseline; or suicidal behaviors within the past year; clinical assessment of significant suicidal risk during subject interview.
• •2. Participation in another concurrent clinical study or within the preceding month.
• •3. Women who are pregnant or who intend to become pregnant during the study or who are currently nursing.
• •4. Vital signs, averaged over 3 readings within 15 minutes, of systolic blood pressure (BP) \>139 mm Hg, diastolic BP \>89 mm Hg, or heart rate \>90 bpm.
• •5. Have any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, prior myocardial infarction, tachycardia, artificial heart valve, QTc \>450 msec at screening, any other clinically significant screening ECG abnormality, or any other significant cardiovascular condition.
• •6. Presence of a gastrointestinal disease that could interfere with absorption of orally-administered TRP 8802.
• •7. Have epilepsy.
• •8. Meet DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features, or Bipolar I or Bipolar II Disorder.
• •9. Family history of psychosis.
• •10. Meet DSM-5 criteria for a moderate or severe alcohol or drug use disorder.
• •11. Positive urine drug screen or alcohol breath test at screening. A repeat test can be conducted at screening or Day -1 at the discretion of the Principal Investigator or delegate.
• •12. Prior adverse effects from psilocybin.
• •13. Currently taking or expected to need prior to the dosing session, UGT1A9 or 1A10 inhibitors (e.g., regorafenib, rifampicin, phenytoin, eltrombopag, mefenamic acid, diflunisal, niflumic acid, sorafenib, isavuconazole, deferasirox, ginseng) and aldehyde or alcohol dehydrogenase inhibitor (e.g., disulfiram).
• •14. Currently taking or testing positive on urine drug screen, drugs of abuse such as amphetamines, buprenorphine, benzodiazepines, cocaine, methamphetamines, Ecstasy (MDMA), morphine, methadone, oxycodone, marijuana, ethyl glucuronide, fentanyl, tramadol, and synthetic cannabinoids (K2).
• •15. Currently taking on a regular (e.g., daily) basis any medications having a primary centrally-acting serotonergic effect, including SSRIs, MAOIs, or serotonin-acting dietary supplements (such as 5 hydroxy tryptophan or St. John's wort). For individuals who have intermittent or PRN use of such medications, the dosing session will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose.
• •16. fMRI subjects: Contraindications to fMRI procedures, per institutional policy.